The C677T polymorphism in the methylentetrahydrofolate reductase gene is associated with methotrexate treatment outcome in the East Bohemian region rheumatoid arthritis population
Authors:
T. Soukup 1; M. Doseděl 2; P. Pávek 3; J. Nekvindová 4; T. Veleta 5; A. Kuběna 2; M. Tošovský 1; J. Vlček 2; P. Bradna 1
Authors place of work:
Univerzita Karlova v Praze, Lékařská fakulta a Fakultní nemocnice v Hradci Králové, II. interní gastroenterologická klinika
1; Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, Katedra sociální a klinické farmacie
2; Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, katedra farmakologie a toxikologie
3; Univerzita Karlova v Praze, Lékařská fakulta a Fakultní nemocnice v Hradci Králové, Ústav klinické biochemie a diagnostiky
4; Fakultní nemocnice Hradec Králové, Oddělení urgentní medicíny
5
Published in the journal:
Čes. Revmatol., 23, 2015, No. 1, p. 4-12.
Category:
Original article
Summary
Methotrexate (MTX) is one of the essential medicines used in the treatment of rheumatoid arthritis (RA). The efficacy of treatment of rheumatoid arthritis with MTX is between 46 % and 65 % (as assessed by ACR 20). Pharmacogenetics deals with genetic predisposition of the patient to respond to the treatment.
The aim of the study was to determine whether single nucleotide polymorphism (SNP) C677T (rs1801133) of the MTHFR gene are predictive of peroral MTX efficacy or are associated with lower change of DAS28 (∆DAS 28) after a 6-month MTX treatment in RA adult patient cohort of the East Bohemian population. The 120 patients were enrolled in the study, all of whom fulfilled the American College of Rheumatology (ACR) 1987 RA criteria, and currently or previously taking MTX oral treatment, either as a monotherapy (n = 65) or in a combination with DMARDs (n = 55). Genotyping was performed using qPCR allelic discrimination. We did not found any association of C677T SNP on MTX treatment inefficacy in dominant model CC versus (CT+TT). However, when ∆DAS 28 was used as a measure of MTX treatment efficacy, MTHFR 677CT genotype was significantly associates with less favourable response to MTX (P = 0.01) in case of MTX monotherapy.
Our data thus shows that C677T SNP might be associated with theless favourable response to low dose MTX treatment.
Key words:
Rheumatoid arthritis, methotrexate, methylentetrahydrofolate reductase, pharmacogenetics, personalized medicine
Zdroje
1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964–975.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492–509.
3. Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib - a bysystematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 510–5.
4. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study-A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
5. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43.
6. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.
7. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39–46.
8. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870–7.
9. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 2525–30.
10. Brinker RR, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(Suppl 61): 33–9.
11. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 1831–47.
12. Hider SL, Mack LF, Shadforth MF, et al. Single nucleotide polymorphisms within MTHFR are associated with abnormal liver function tests in RA patients recieving MTX. Rheumatology 2006; 45(Suppl 1): 104.
13. Owen SA, Lunt M, Bowes J, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 2013; 13: 137–47.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
15. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34–40.
16. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56: 1765–75.
17. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22–9.
18. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 1258–60.
19. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008; 9: 439–51.
20. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 2006; 124: 521–6.
21. Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006; 33: 1266–74.
22. Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007; 8: 1551–9.
23. Lee YH, Song GG. Association between the C677T and A1298C polymorphism of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a metaanalysis. Clin Drug Investig 2010; 30: 101–8.
24. Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007; 17: 383–90.
25. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539–45.
26. Xiao H, Xu J, Zhou X, et al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 728–33.
27. Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 2009; 27: 499–502.
28. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3095–103.
29. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–3.
30. Liu N, Jiang J, Song YJ, et al. Impact of MTHFR polymorphisms on methylation of MGMT in glioma patients from Northeast China with different folate levels.Genet Mol Res 2013; 12: 5160–71.
31. Szabó GV. The role and importance of gene polymorphisms in the development of atherosclerosis. Interv Med Appl Sci 2013; 5: 46–51.
32. Karata S, Aydin Y, Ocer F, Buyru A, Balci H. Hereditary thrombophilia, anti-beta2 glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67: 251–5.
33. Tsai SJ, Hong CJ, Yeh HL, Liou YJ, Yang AC, Liu ME, Hwang JP. Heterozygote advantage of the MTHFR C677T polymorphism on specific cognitive performance in elderly Chinese males without dementia. Dement Geriatr Cogn Disord. 2011; 32: 159–63.
34. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094–9.
35. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002; 29: 1631–8.
36. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21(Suppl 31): 178–85.
37. Wilcken B, Bamforth F, Li Z, et al. Geografical and ethnic variation og the 677C-T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2004; 40: 619-25.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2015 Číslo 1
Najčítanejšie v tomto čísle
- Efficacy and safety of intra-articular injection of depot corticosteroids in rheumatic diseases
- Systemic lupus erythematosus – a report of an unusual case with hemorrhagic manifestations
- Prospects for the treatment of osteoarthritis
- The C677T polymorphism in the methylentetrahydrofolate reductase gene is associated with methotrexate treatment outcome in the East Bohemian region rheumatoid arthritis population